Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30597578 | 0.89 | POLB (1.00) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL30597589 | 0.85 | POLB (0.82) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL1936056 | 0.83 | ALDH1A1 (0.71) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL10511025 | 0.83 | KMT2A (0.72) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL29419157 | 0.83 | ALDH1A1 (0.70) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL20300606 | 0.82 | ALDH1A1 (0.69) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL14830534 | 0.80 | KMT2A (0.72) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL13634694 | 0.79 | KMT2A (1.00) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL18619386 | 0.79 | POLB (0.72) | ALDH1A1POLBKMT2AMAPK1PKM | |
| SCHEMBL30004213 | 0.78 | ALDH1A1 (0.63) | ALDH1A1POLBKMT2AMAPK1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020045541-A1 | CHROMATOGRAPHY CARRIER | JSR株式会社 | 2020-03-05 | — | — | WO | disclosed |
| US-7750129-B2 | Process for the purification of antibodies | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7320755-B2 | Method of preparing ligands for hydrophobic interaction chromatography | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2008-01-22 | — | — | US | disclosed |
| US-20070167613-A1 | Process for the purification of antibodies | CYTIVA BIOPROCESS R&D AB (SE) | 2007-07-19 | — | — | US | disclosed |
| EP-1718386-A1 | A PROCESS FOR THE PURIFICATION OF ANTIBODIES | GE Healthcare Bio-Sciences AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082483-A1 | A PROCESS FOR THE PURIFICATION OF ANTIBODIES | GE HEALTHCARE BIO-SCIENCES AB (SE) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167613-A1 | Process for the purification of antibodies | FCGR1A, FCGRT, CD47 | ALDH1A1 2803/4885POLB 4008/4885KMT2A 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.